首页> 外国专利> recombinant proteins for use as endotoxinbiosensor as antimicrobial and antiendotoxin therapeutic agents and for the removal of endotoxin

recombinant proteins for use as endotoxinbiosensor as antimicrobial and antiendotoxin therapeutic agents and for the removal of endotoxin

机译:重组蛋白,用作内毒素生物传感器,用作抗微生物和抗内毒素治疗剂,并用于去除内毒素

摘要

RECOMBINANT PROTEINS AND PEPTIDES FOR ENDOTOXIN BIOSENSORS ENDOTOXIN REMOVAL AND ANTI-MICROBIAL & ANTI-ENDOTOXIN THERAPEUTICS Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing, and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi- 3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 µM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 µM of SSCrFCES inhibits the LPS-induced secretion of hTNF-a and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml/minute. The LD90 of SSCrFCES for LPS lethality in mice is achieved at 2 µM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin- induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials. Further embodied in this application is the use of sushi peptides or sushi recombinatnt proteins to remove endotoxin from liquids.
机译:公开了用于内毒素的生物传感器内毒素的去除以及抗微生物和抗内毒素治疗的重组蛋白和肽,公开了因子C的重组片段。这些蛋白质和肽在识别,结合,中和和去除内毒素方面显示出巨大的潜力。这些分子因此可以用于抗微生物,抗内毒素和抗败血症治疗。 SSCrFCES是一个38 kDa的蛋白质,代表因子C的LPS结合域。使用基于ELISA的分析以及表面等离子体共振分析了SSCrFCES结合脂质A的能力。类似地对SSCrFC-sushi-1,2,3-GFP,SSCrFC-sushi-1GFP和SSCrFC-sushi-3GFP进行的表面等离子体共振证实了它们对内毒素的优越亲和力。 SSCrFCES对200 EU内毒素的50%内毒素中和浓度为0.069 µM,表明SSCrFCES是LAL凝血级联的有效抑制剂。尽管被人血清部分减弱,但低至1 µM的SSCrFCES抑制TPS-1和人外周血单个核细胞的脂多糖诱导的hTNF-a和hIL-8分泌,其效力比多粘菌素B更强。 -细胞毒性,清除率为4.7毫升/分钟。 SSCrFCES对小鼠LPS致死性的LD90为2 µM。这些结果证明了SSCrFCES在体外和体内的内毒素中和能力,以及其在治疗内毒素诱导的败血性休克中的潜力。在本申请中还体现了sushi肽及其突变体衍生物作为有效的抗菌剂的用途。在本申请中进一步体现的是使用寿司肽或寿司重组蛋白从液体中去除内毒素。

著录项

  • 公开/公告号DE60045556D1

    专利类型

  • 公开/公告日2011-03-03

    原文格式PDF

  • 申请/专利权人 NATIONAL UNIVERSITY OF SINGAPORE;

    申请/专利号DE20006045556T

  • 发明设计人 DING JEAK LING;HO BOW;TAN NGUAN SOON;

    申请日2000-10-13

  • 分类号C12N15/57;A61K38/48;C07K19;C12N9/64;C12N15/62;C12Q1/37;

  • 国家 DE

  • 入库时间 2022-08-21 17:46:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号